ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.687,88
-0,21%
S&P 500
5.321,41
0,25%
Dow Jones
39.872,99
0,17%
Euro vs US Dollar
1,08409
-0,13%
Bitcoin
70.142,19
0,02%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Oric Pharmaceuticals Inc (ORIC)

  7. Oric Pharmaceuticals Inc (ORIC) News

ORIC

Oric Pharmaceuticals (ORIC)

Oric Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ORIC
DatumZeitQuelleÜberschriftSymbolFirma
06/05/202422h20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ORICOric Pharmaceuticals Inc
06/05/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORICOric Pharmaceuticals Inc
06/05/202422h05GlobeNewswire Inc.ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational UpdatesNASDAQ:ORICOric Pharmaceuticals Inc
03/05/202422h30GlobeNewswire Inc.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ORICOric Pharmaceuticals Inc
15/04/202422h15GlobeNewswire Inc.ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLCNASDAQ:ORICOric Pharmaceuticals Inc
08/04/202414h00GlobeNewswire Inc.ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:ORICOric Pharmaceuticals Inc
05/04/202422h30GlobeNewswire Inc.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ORICOric Pharmaceuticals Inc
04/04/202422h30GlobeNewswire Inc.ORIC Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:ORICOric Pharmaceuticals Inc
11/03/202422h28Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:ORICOric Pharmaceuticals Inc
11/03/202421h20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ORICOric Pharmaceuticals Inc
11/03/202421h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORICOric Pharmaceuticals Inc
11/03/202421h05GlobeNewswire Inc.ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational UpdatesNASDAQ:ORICOric Pharmaceuticals Inc
06/03/202422h30GlobeNewswire Inc.ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma ConferenceNASDAQ:ORICOric Pharmaceuticals Inc
05/03/202422h30GlobeNewswire Inc.ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:ORICOric Pharmaceuticals Inc
01/03/202422h30GlobeNewswire Inc.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ORICOric Pharmaceuticals Inc
14/02/202422h30GlobeNewswire Inc.ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership SummitNASDAQ:ORICOric Pharmaceuticals Inc
05/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORICOric Pharmaceuticals Inc
02/02/202422h30GlobeNewswire Inc.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ORICOric Pharmaceuticals Inc
31/01/202422h30GlobeNewswire Inc.ORIC Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:ORICOric Pharmaceuticals Inc
30/01/202418h12Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ORICOric Pharmaceuticals Inc
26/01/202422h58Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ORICOric Pharmaceuticals Inc
25/01/202419h24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ORICOric Pharmaceuticals Inc
22/01/202415h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORICOric Pharmaceuticals Inc
22/01/202414h30GlobeNewswire Inc.ORIC Pharmaceuticals Announces $125 Million Private Placement FinancingNASDAQ:ORICOric Pharmaceuticals Inc
09/01/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORICOric Pharmaceuticals Inc
08/01/202414h30GlobeNewswire Inc.ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming MilestonesNASDAQ:ORICOric Pharmaceuticals Inc
02/01/202422h30GlobeNewswire Inc.ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ORICOric Pharmaceuticals Inc
29/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORICOric Pharmaceuticals Inc
15/12/202322h32Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ORICOric Pharmaceuticals Inc
11/12/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORICOric Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ORIC

Kürzlich von Ihnen besucht

EU
NL0015001RM6
Netherlands Nl Strip 15j...
COIN
HCOGBP
TSXV
BAT
Batero Gold
BIT
P1JRE8
BNP Paribas Issuance
NASDAQ
EMBCV
Embecta
DBI
I2UZ
XMWMVEUE1CUSDINAV
ASX
VRLN
COIN
FINUST
DeFiner
LSE
51HW
Lloyds Bk. 38
LSE
10PZ
Roy.bk.can. 36
UNSW
SKULLETH
Skull
BIT
UR9ZNE
UniCredit Bank
BIT
S29044
Societe Generale Effekten
AMEX
FAUG
FT Vest US Equity Buffer...
LSE
PUMC
Puma Vct Iii
LSE
13RA
Axa
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten